Evidence map›Paper›PMID 39129964›Full record

ArticleInternational journal of chronic obstructive pulmonary disease2024

Real-World Effectiveness of Benralizumab Among Patients with Asthma and Concomitant Chronic Obstructive Pulmonary Disease.

Donna D Carstens, Diego J Maselli, Erin E Cook, Fan Mu, Jingyi Chen, Danni Yang, Jessica Karacz DeMartino, Yen Chung

Abstract readLetter
In one paragraph

Article in International journal of chronic obstructive pulmonary disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Persistent airway obstruction in severe eosinophilic asthma: targeting interleukin-5 and eosinophils.European respiratory review : an official journal of the European Respiratory Society · 2025
    Review
  5. Observational
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Donna D CarstensRespiratory & Immunology, AstraZeneca, Wilmington, DE, USA.
Diego J MaselliDivision of Pulmonary Diseases & Critical Care, University of Texas Health, San Antonio, TX, USA.
Erin E CookHealth Economic and Outcomes Research, Analysis Group, Boston, MA, USA.
Fan MuHealth Economic and Outcomes Research, Analysis Group, Boston, MA, USA.ORCID 0000-0003-0252-0387
Jingyi ChenHealth Economic and Outcomes Research, Analysis Group, Boston, MA, USA.
Danni YangHealth Economic and Outcomes Research, Analysis Group, Boston, MA, USA.
Jessica Karacz DeMartinoRespiratory & Immunology, AstraZeneca, Wilmington, DE, USA.
Yen ChungRespiratory & Immunology, AstraZeneca, Wilmington, DE, USA.ORCID 0000-0003-1587-4774

Funding

AstraZeneca.
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Anti-Asthmatic AgentsAntibodies, Monoclonal, HumanizedAsthmaPulmonary Disease, Chronic ObstructiveAgedFemaleForced Expiratory VolumeHumansLungMaleMiddle AgedRetrospective StudiesTime FactorsTreatment OutcomeAnti-Asthmatic AgentsAntibodies, Monoclonal, Humanizedbenralizumab

Identifiers

PMID39129964
PMCPMC11317043

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.